The researchers have proved the anti-tumor effects of the drug on immunodeficient mice.
The new compound and its derivatives enabled the researchers to reduce tumor activity by 50 percent after 41 days of treatment with the drugadministered twice a week, to cancer pancreatic studies with induced tumors.
They have also managed to successfully describe the mechanisms by which the drug acts on the cancer stem cells CSCs. The Córdoba-based company Canvax Biotech has also participated in the development of the patent.
A non-toxic drug One of the major advantages of the drug is that it is non-toxic. Despite being administered to the mice in high concentrations milligrams per kilono adverse effects were observed in the healthy cells.
Moreover, from a îndepărtați papiloma Ulyanovsk perspective this anti-tumor drug can be successfully produced in large quantities.
Also it is difficult to make the differential diagnosis with the pseudotumoral chronic pancreatitis, which has similar imagistic and clinical features, so surgery with hystopathologic diagnosis is needed. The preoperative staging of the pancreatic cancer has a limited accuracy max.
The researchers were able to obtain the required amount of the synthesis in just five days. In the initial phases of their research, the scientists had already managed to create an effective drug called Bozepinib for treating cancer stem cellsbut the process involved in its chemical synthesis was lengthy and required a great deal of time to produce very small quantities of the drug.
Aceste exemple pot conține cuvinte vulgare. Aceste exemple pot conține termeni colocviali.
Having completed structural modifications of the drug—Bozepinib by making changes to its molecular architecturethey have successfully created a compound which maintains the biological activity of its predecessor as an effective anti-tumor drug, but which can also be synthesized and produced on a grand scale—a fundamental condition for the drug's commercial development.
In order to be able to test the new drug on mice and gauge its effectiveness on human tumors, first of all they had to inject human tumor cells into immunodeficient mice to ensure they did not reject these cancerous cells.
- UGR scientists patent an effective drug for treating breast, colon, and skin cancers
- Hpv virus how transmitted
Following cancer pancreatic studies treatment, they discovered that some of the compounds effectively inhibited the growth of the tumor cells and the migration ability of these cells to other healthy tissues, considerably diminishing the likelihood of metastasis. The drug directly targets CSCs without affecting the healthy cellsa huge advantagewhen cancer pancreatic studies to other cancer treatments such as chemotherapy.
AlthoughCSCs are only found in small quantities in tumors, from a clinical perspective the ability to target them directly is of fundamental importance, given that they are responsible for originally causing the tumor, relapses and resistance to anticancer treatments.
The next step: Lungs and pancreas Having proved the pre-clinical effectiveness of the new drug in treating cancer stem cells in breast, colon, and skin cancers, the scientists will now proceed to study the drug's effect on lung and pancreas cancers, two of the most aggressive types.
UGR scientists patent an effective drug for treating breast, colon, and skin cancers
They must also complete further ADME-Tox "absorption, distribution, metabolism, excretion and toxicity" studies of the compound's behavior within the organism, a necessary step before carrying out clinical trials. RSC Adv.
García-Rubiño, M. Núñez-Carretero, D.
Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? Cancer Treat Rev.
Choquesillo-Lazarte, J. García-Ruiz, Yolanda Madrid, J.
Death rates from pancreatic cancer predicted to rise in Europe in - Pancreatic cancer news
Campos, Ana Sánchez, María A. García, Juan A. Oncotarget,5 11 Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.
The content is provided for information purposes only.